Interestingly, although some alterations such as ERBB2 and MET amplifications are only seen in adenocarcinomas (both intestinal and signet-cell carcinoma, and in both gastric and oesophageal tumors), EGFR and CCND1 amplifications and PIK3CA alterations were found in patients with both adenocarcinoma and squamous cell histologies. Here, MET is linked to adenocarcinoma.